

June 2006 DURB Meeting Summary

| Issue | Attachment* | Action | Notes |
|---------------------------------|------------------|----------|--|
| Roll Call | | | Present: Dr. Swee, Dr. Goosen, Dr. Woodward, Dr. Marcus, Ms, Rodriquez, Mr. Schafer, Dr. Moynihan, Dr. Lichtbroun Absent: Dr. Cavalieri, Dr. Moore, Ms. Olson, Dr. Barberio, Dr. Condoluci, Dr. Gochfeld |
| Review of minutes | Pages 3-7; Tab 1 | Approved | Minutes from the April, 2006 meeting were approved. A correction to the transcript was noted: page 18, line 35 company should be accompanying. The Board voted to change the time of future meetings to 10:00 am. Public notice will be arranged. |
| Secretary's Report | Page 9; Tab 2 | | Patricia Hafitz reported that the recommendation from the February 2006 meeting was signed by both Commissioners and the pilot program of OTC PPIs began June 6. Utilization data will be presented at the October meeting. The programming for the recommendations from the October 2005 meeting has been completed although the edits affected are currently turned off while Unisys acquires sufficient staff. Both Commissioners signed the recommendations from the April 2006 meeting; programming has not been completed yet. The PPI newsletter is posted on the DURB website, and mailing will be targeted to the prescribers who have been identified as the top prescribers for these drugs. It was suggested that pharmacies and education offices receive mailings also. Disease Management is moving forward; orientation letters have gone out; intervention letters have not yet gone out. The reminder letters for Plavix® have not yet started to go out, the procedure for identification and notification is still under development. The Annual Report for SFY 05 will be distributed via e-mail to Board members once approved by DMAHS. |
| Business | | | |
| A. Data on methadone/opioid use | | Tabled | The data will be presented at the October meeting due to difficulties in reporting. |

June 2006 DURB Meeting Summary

| Issue | Attachment* | Action | Notes |
|--|-----------------------|----------------|--|
| B. First-dose claims | Page 11; Tab 3 | | The report demonstrated the doses that were present on new (first-dose) claims, if the Board should be interested in this type of report. |
| C. Action Items | | | |
| 1. Tizanidine | Pages 13-20; Tab 4 | Recommendation | The Board recommended that the State apply first fill edit on doses ≥ 8 mg per day without claims history for tizanidine or other skeletal muscle relaxants, and the maximum dose edit on doses > 24 mg per day. |
| 2. Non-benzodiazepine sleep medications | Pages 21-74; Tab 5 | Recommendation | The Board recommended that an educational newsletter be done regarding the use of sleep medications instead a applying a duration edit at this time. This will be accomplished through the Office of Utilization Management with the next round of students. |
| 3. Oxandrin® | Pages 75-78; Tab 6 | Recommendation | The Board approved recommending the protocol presented with the addition of patient's weight as a monitoring parameter, and the criteria for denial modified to be "Failure to meet approval criteria without additional information to justify medical necessity" |
| 4. Forteo® | Pages 79-104; Tab 7 | Recommendation | The Board recommended that an educational newsletter be done on the medications used to treat osteoporosis, instead of a protocol. This will be accomplished through the Office of Utilization Management with the next round of students. |
| D. Informational Highlights | | | |
| 1. Edit update | Page 105; Tab 8 | | Table updates were noted and accepted |
| 2. Top 200 drugs | Pages 107-114; Tab 9 | | |
| 3. Unisys reports | Pages 115-122; Tab 10 | | |
| E. Action Items | | | |
| 1. Recommendations (April 2006) 2. Annual report 3. Methadone/opioid 4. Plavix 5. PPIs | | | 1. Proceed with programming 2. E-mail draft to Board members once approved by DMAHS 3. Analyze data regarding chronic vs short-term use 4. Implement system for sending reminder letters 5. Report utilization data which includes OTC |

June 2006 DURB Meeting Summary

| Issue | Attachment* | Action | Notes |
|--------------------------------|-------------|--------|--|
| 6. Tizanidine | | | 6. Recommendation to Commissioner; implement |
| 7. Oxandrolone | | | 7. Recommendation to Commissioner with modification; implement |
| 8. Non-benzo sleep medications | | | 8. Prepare newsletter |
| 9. Forteo® | | | 9. Prepare newsletter |